The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Breast Cancer Liquid Biopsy Market Research Report 2024
Synopsis
Breast Cancer Liquid Biopsy can be usually used in breast biopsy, based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers.
The global Breast Cancer Liquid Biopsy market was valued at US$ 1597.5 million in 2023 and is anticipated to reach US$ 2248.5 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
North American market for Breast Cancer Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Breast Cancer Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Breast Cancer Liquid Biopsy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Breast Cancer Liquid Biopsy include QIAGEN, Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Genomic Health, Thermo Fisher Scientific, Illumina and Biocept, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Breast Cancer Liquid Biopsy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Breast Cancer Liquid Biopsy.
Report Scope
The Breast Cancer Liquid Biopsy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Breast Cancer Liquid Biopsy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Breast Cancer Liquid Biopsy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
QIAGEN
Roche Diagnostics
Bio-Rad Laboratories
Myriad Genetics
Menarini Silicon Biosystems
Genomic Health
Thermo Fisher Scientific
Illumina
Biocept
Trovagene
Guardant Health
RainDance Technologies
MDx Health
Segment by Type
Circulating Tumor Cells (CTCs)
Cell-Free DNA (CfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers
Segment by Application
Hospitals
Diagnostic Centers
Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Breast Cancer Liquid Biopsy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Breast Cancer Liquid Biopsy can be usually used in breast biopsy, based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers.
The global Breast Cancer Liquid Biopsy market was valued at US$ 1597.5 million in 2023 and is anticipated to reach US$ 2248.5 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
North American market for Breast Cancer Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Breast Cancer Liquid Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Breast Cancer Liquid Biopsy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Breast Cancer Liquid Biopsy include QIAGEN, Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Genomic Health, Thermo Fisher Scientific, Illumina and Biocept, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Breast Cancer Liquid Biopsy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Breast Cancer Liquid Biopsy.
Report Scope
The Breast Cancer Liquid Biopsy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Breast Cancer Liquid Biopsy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Breast Cancer Liquid Biopsy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
QIAGEN
Roche Diagnostics
Bio-Rad Laboratories
Myriad Genetics
Menarini Silicon Biosystems
Genomic Health
Thermo Fisher Scientific
Illumina
Biocept
Trovagene
Guardant Health
RainDance Technologies
MDx Health
Segment by Type
Circulating Tumor Cells (CTCs)
Cell-Free DNA (CfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers
Segment by Application
Hospitals
Diagnostic Centers
Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Breast Cancer Liquid Biopsy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Breast Cancer Liquid Biopsy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Circulating Tumor Cells (CTCs)
1.2.3 Cell-Free DNA (CfDNA)
1.2.4 Extracellular Vesicles (EVs)
1.2.5 Other Circulating Biomarkers
1.3 Market by Application
1.3.1 Global Breast Cancer Liquid Biopsy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Diagnostic Centers
1.3.4 Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Breast Cancer Liquid Biopsy Market Perspective (2019-2030)
2.2 Breast Cancer Liquid Biopsy Growth Trends by Region
2.2.1 Global Breast Cancer Liquid Biopsy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Breast Cancer Liquid Biopsy Historic Market Size by Region (2019-2024)
2.2.3 Breast Cancer Liquid Biopsy Forecasted Market Size by Region (2025-2030)
2.3 Breast Cancer Liquid Biopsy Market Dynamics
2.3.1 Breast Cancer Liquid Biopsy Industry Trends
2.3.2 Breast Cancer Liquid Biopsy Market Drivers
2.3.3 Breast Cancer Liquid Biopsy Market Challenges
2.3.4 Breast Cancer Liquid Biopsy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Breast Cancer Liquid Biopsy Players by Revenue
3.1.1 Global Top Breast Cancer Liquid Biopsy Players by Revenue (2019-2024)
3.1.2 Global Breast Cancer Liquid Biopsy Revenue Market Share by Players (2019-2024)
3.2 Global Breast Cancer Liquid Biopsy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Breast Cancer Liquid Biopsy Revenue
3.4 Global Breast Cancer Liquid Biopsy Market Concentration Ratio
3.4.1 Global Breast Cancer Liquid Biopsy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Breast Cancer Liquid Biopsy Revenue in 2023
3.5 Breast Cancer Liquid Biopsy Key Players Head office and Area Served
3.6 Key Players Breast Cancer Liquid Biopsy Product Solution and Service
3.7 Date of Enter into Breast Cancer Liquid Biopsy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Breast Cancer Liquid Biopsy Breakdown Data by Type
4.1 Global Breast Cancer Liquid Biopsy Historic Market Size by Type (2019-2024)
4.2 Global Breast Cancer Liquid Biopsy Forecasted Market Size by Type (2025-2030)
5 Breast Cancer Liquid Biopsy Breakdown Data by Application
5.1 Global Breast Cancer Liquid Biopsy Historic Market Size by Application (2019-2024)
5.2 Global Breast Cancer Liquid Biopsy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Breast Cancer Liquid Biopsy Market Size (2019-2030)
6.2 North America Breast Cancer Liquid Biopsy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Breast Cancer Liquid Biopsy Market Size by Country (2019-2024)
6.4 North America Breast Cancer Liquid Biopsy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Breast Cancer Liquid Biopsy Market Size (2019-2030)
7.2 Europe Breast Cancer Liquid Biopsy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Breast Cancer Liquid Biopsy Market Size by Country (2019-2024)
7.4 Europe Breast Cancer Liquid Biopsy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Breast Cancer Liquid Biopsy Market Size (2019-2030)
8.2 Asia-Pacific Breast Cancer Liquid Biopsy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Breast Cancer Liquid Biopsy Market Size by Region (2019-2024)
8.4 Asia-Pacific Breast Cancer Liquid Biopsy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Breast Cancer Liquid Biopsy Market Size (2019-2030)
9.2 Latin America Breast Cancer Liquid Biopsy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Breast Cancer Liquid Biopsy Market Size by Country (2019-2024)
9.4 Latin America Breast Cancer Liquid Biopsy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Breast Cancer Liquid Biopsy Market Size (2019-2030)
10.2 Middle East & Africa Breast Cancer Liquid Biopsy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Breast Cancer Liquid Biopsy Market Size by Country (2019-2024)
10.4 Middle East & Africa Breast Cancer Liquid Biopsy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 QIAGEN
11.1.1 QIAGEN Company Detail
11.1.2 QIAGEN Business Overview
11.1.3 QIAGEN Breast Cancer Liquid Biopsy Introduction
11.1.4 QIAGEN Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.1.5 QIAGEN Recent Development
11.2 Roche Diagnostics
11.2.1 Roche Diagnostics Company Detail
11.2.2 Roche Diagnostics Business Overview
11.2.3 Roche Diagnostics Breast Cancer Liquid Biopsy Introduction
11.2.4 Roche Diagnostics Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.2.5 Roche Diagnostics Recent Development
11.3 Bio-Rad Laboratories
11.3.1 Bio-Rad Laboratories Company Detail
11.3.2 Bio-Rad Laboratories Business Overview
11.3.3 Bio-Rad Laboratories Breast Cancer Liquid Biopsy Introduction
11.3.4 Bio-Rad Laboratories Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.3.5 Bio-Rad Laboratories Recent Development
11.4 Myriad Genetics
11.4.1 Myriad Genetics Company Detail
11.4.2 Myriad Genetics Business Overview
11.4.3 Myriad Genetics Breast Cancer Liquid Biopsy Introduction
11.4.4 Myriad Genetics Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.4.5 Myriad Genetics Recent Development
11.5 Menarini Silicon Biosystems
11.5.1 Menarini Silicon Biosystems Company Detail
11.5.2 Menarini Silicon Biosystems Business Overview
11.5.3 Menarini Silicon Biosystems Breast Cancer Liquid Biopsy Introduction
11.5.4 Menarini Silicon Biosystems Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.5.5 Menarini Silicon Biosystems Recent Development
11.6 Genomic Health
11.6.1 Genomic Health Company Detail
11.6.2 Genomic Health Business Overview
11.6.3 Genomic Health Breast Cancer Liquid Biopsy Introduction
11.6.4 Genomic Health Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.6.5 Genomic Health Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Breast Cancer Liquid Biopsy Introduction
11.7.4 Thermo Fisher Scientific Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Illumina
11.8.1 Illumina Company Detail
11.8.2 Illumina Business Overview
11.8.3 Illumina Breast Cancer Liquid Biopsy Introduction
11.8.4 Illumina Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.8.5 Illumina Recent Development
11.9 Biocept
11.9.1 Biocept Company Detail
11.9.2 Biocept Business Overview
11.9.3 Biocept Breast Cancer Liquid Biopsy Introduction
11.9.4 Biocept Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.9.5 Biocept Recent Development
11.10 Trovagene
11.10.1 Trovagene Company Detail
11.10.2 Trovagene Business Overview
11.10.3 Trovagene Breast Cancer Liquid Biopsy Introduction
11.10.4 Trovagene Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.10.5 Trovagene Recent Development
11.11 Guardant Health
11.11.1 Guardant Health Company Detail
11.11.2 Guardant Health Business Overview
11.11.3 Guardant Health Breast Cancer Liquid Biopsy Introduction
11.11.4 Guardant Health Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.11.5 Guardant Health Recent Development
11.12 RainDance Technologies
11.12.1 RainDance Technologies Company Detail
11.12.2 RainDance Technologies Business Overview
11.12.3 RainDance Technologies Breast Cancer Liquid Biopsy Introduction
11.12.4 RainDance Technologies Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.12.5 RainDance Technologies Recent Development
11.13 MDx Health
11.13.1 MDx Health Company Detail
11.13.2 MDx Health Business Overview
11.13.3 MDx Health Breast Cancer Liquid Biopsy Introduction
11.13.4 MDx Health Revenue in Breast Cancer Liquid Biopsy Business (2019-2024)
11.13.5 MDx Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
